Editas (EDIT) EVP/CSO Linda Burkly Sells 709 Shares

What Happened
Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine (EDIT), sold 709 shares on September 3, 2026. The sale was reported at a weighted-average price of $3.04 per share for total proceeds of approximately $2,153. This transaction was a sale (not a purchase) and was executed to satisfy tax withholding obligations tied to restricted stock unit (RSU) vesting.

Key Details

• Transaction date: 2026-09-03; filing date: 2026-09-04 (appears timely).
• Transaction type: Sale (code S); reported as "open market or private sale."
• Shares sold: 709; weighted-average price: $3.04; total proceeds: ~$2,153.
• Price range / execution detail: Executed in multiple trades at $3.0050–$3.0372; weighted average reported. Reporting person will provide full trade-by-trade details upon request (footnote).
• Reason / plan: Sale effected under a durable automatic sales instruction plan adopted July 3, 2023, to cover tax withholding for RSUs that vested on Sept 2, 2026; not a discretionary trade by the reporting person (tax-withholding/sell-to-cover).
• Shares owned after transaction: Not specified in the filing.

Context
This was a routine sell-to-cover for tax withholding on vested RSUs rather than a voluntary market-timing sale. Such transactions are common following equity vesting and generally do not by themselves signal a change in an insider’s view of the company. The dollar amount involved is small (~$2.2k).